Details
Category: Volume 07 Issue 10 October 2019
Hits: 974

Title: Altered Expressions of Matrix Metalloproteinases 2 and 9 in Cervical Carcinoma with high risk HPV-16 and HPV-18 in a South Indian Population: A Pilot Study

Authors: Thirumurugan @ Murali. P, K. Santha, R. Ramesh, S. Sethupathy, Vickneshwaran V

 DOI: https://dx.doi.org/10.18535/jmscr/v7i10.96

Abstract

  

Cervical cancer is one of the commonest cancer affecting women worldwide.  HPV types 16 and 18 shows high risk for the development of both squamous cell carcinoma and adenocarcinoma of the cervix.  Serum tumor markers are useful in screening cancers and also for assessing the prognosis of the disease.  However, no specific tumor markers have been found suitable for the detection of ca cervix. Tumor cells secrete certain enzymes such as Matrix metalloproteinases (MMPs) which degrade the ECM necessary for neovascularization by growth factors such as vascular endothelial growth factors (VEGF).  MMP-2 (72 kDa gelatinase) and MMP-9 (92 kDa gelatinase) play a vital role in ECM degradation.  The aim of the present study was to determine plasma levels of VEGF, MMP-2 and MMP-9 and their relative gene expression in patients with HPV16 & HPV18 positive Cancer cervix patients in relation to healthy controls. 

Keywords: Cervical Carcinoma. MMP9, HPV-16, HPV-16.

References

  1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol Off J Eur Soc Med Oncol. 2011 Dec;22(12):2675–86.
  2. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta Int J Clin Chem. 2015 May 20;445:7–11.
  3. Maver PJ, Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018 28;36(36):5416–23.
  4. Szarewski A. HPV vaccination and cervical cancer. Curr Oncol Rep. 2012 Dec;14(6):559–67.
  5. Gradíssimo A, Burk RD. Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Rev Mol Diagn. 2017 Apr;17(4):379–91.
  6. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003 Sep 15;68(6):1075–82.
  7. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015 Sep;5(5):402–18.
  8. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 Oct;2(10):737–44.
  9. Johansson N, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci CMLS. 2000 Jan 20;57(1):5–15.
  10. Vihinen P, Kähäri V-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002 May 10;99(2):157–66.
  11. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005 Apr;87(3–4):287–97.
  12. Nagase H, Karamanos N. Metalloproteinases in health and disease: challenges and the future prospects. FEBS J. 2011 Jan;278(1):1.
  13. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005 May 25;1755(1):37–69.
  14. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Nov 1;27(31):5287–97.
  15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001 Dec;25(4):402–8.
  16. Sánchez-Martín V, Jiménez-García L, Herranz S, Luque A, Acebo P, Amesty Á, et al. α-Hispanolol Induces Apoptosis and Suppresses Migration and Invasion of Glioblastoma Cells Likely via Downregulation of MMP-2/9 Expression and p38MAPK Attenuation. Front Pharmacol. 2019;10:935.
  17. Li C, Li Y, Sui L, Wang J, Li F. Phenyllactic acid promotes cell migration and invasion in cervical cancer via IKK/NF-κB-mediated MMP-9 activation. Cancer Cell Int. 2019;19:241.
  18. Mao F, Niu X-B, Gu S, Ji L, Wei B-J, Wang H-B. The association between matrix metalloproteinase-7 genetic variant and bladder cancer risk in a Chinese Han population. Clin Exp Med. 2019 Oct 1;
  19. Lin D-D, Shen Y, Qiao S, Liu W-W, Zheng L, Wang Y-N, et al. Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma. Front Oncol. 2019;9:862.
  20. Lim H-J, Park J, Um J-Y, Lee S-S, Kwak H-J. Zileuton, a 5-Lipoxygenase Inhibitor, Exerts Anti-Angiogenic Effect by Inducing Apoptosis of HUVEC via BK Channel Activation. Cells. 2019 Sep 30;8(10).
  21. Zajkowska M, Głażewska EK, Będkowska GE, Chorąży P, Szmitkowski M, Ławicki S. Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis. Mediators Inflamm. 2016;2016:5962946.
  22. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer [Internet]. [cited 2019 Oct 3]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771393/
  23. Guo H, Dai Y, Wang A, Wang C, Sun L, Wang Z. Association between expression of MMP-7 and MMP-9 and pelvic lymph node and para-aortic lymph node metastasis in early cervical cancer. J Obstet Gynaecol Res. 2018 Jul;44(7):1274–83.
  24. Rahmani AH, Babiker AY, Alsahli MA, Almatroodi SA, Husain NEOS. Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma. Open Access Maced J Med Sci. 2018 Feb 15;6(2):263–8.

Corresponding Author

Dr R.Ramesh

Professor, Department of Biochemistry, JIPMER, Puducherry, India